Will gained a PhD in Immunology and Virology sponsored by Unilever (UniPath) in 1993, before holding a post-doctoral position at the National Institute of Biological Standards and Control (NIBSC). He went on to Procter & Gamble Healthcare, where he was responsible for clinical development in a number of therapeutic areas. He led and delivered programmes in North America, Europe, South Africa and China. He moved into biotech ten years ago.
In addition to CTS, Will is chairman of a prostate cancer drug discovery company, CellCentric and a non-executive director of a cardiovascular research business, PlaqueTec. In 2011 he was appointed by the UK’s Science Minister to the Council of the BBSRC, the UK’s leading funder of bioscience research. In 2012 Will was elected to the Board of the BioIndustry Association and sits on both the Executive and Audit Committees. He holds a Masters degree in Clinical Research as well as an MBA from London Business School.